NovaBridge Biosciences

NBPSEC EDGAR

Pharmaceutical Preparations(E9)CIK: 1778016

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	—	$30.0M	$53.8M
Cost of Revenue	—	$46.4M	$46.4M	$0.00	—
Research and Development Expense	—	$1.2B	$984.7M	$840.4M	$43.6M
Operating Expenses	$51.5M	—	—	—	—
Operating Income (Loss)	-$53.1M	—	—	—	—
Interest Expense	—	$0.00	$957.0K	$3.0M	$11.7M
Other Nonoperating Income (Expense)	—	$83.2M	$412.9M	-$20.2M	-$16.8M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	—	$4.1B	$5.6B	$6.3B	$1.7B
Assets, Current	—	$3.6B	$4.8B	$5.3B	$1.4B
Cash and Cash Equivalents, at Carrying Value	—	$3.2B	$3.5B	$4.8B	$1.1B
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	$33.1M	$130.5M	$130.5M
Inventory, Net	—	—	$27.2M	$0.00	—
Liabilities	—	$1.2B	$1.0B	$706.6M	$668.1M
Liabilities, Current	—	$758.2M	$624.0M	$576.1M	$588.5M

Concept	FY2023	FY2022	FY2021	FY2020	FY2019
Net Cash Provided by (Used in) Operating Activities	-$973.1M	$433.6M	-$868.0M	-$280.7M	-$252.2M
Net Cash Provided by (Used in) Investing Activities	-$727.2M	-$201.9M	$212.5M	$9.5M	-$157.7M
Net Cash Provided by (Used in) Financing Activities	$593.9M	$3.4B	$152.7M	$1.5B	$758.6M
Payments to Acquire Property, Plant, and Equipment	$29.9M	$8.0M	$12.2M	$14.4M	$20.3M
Payments for Repurchase of Equity	$21.2M	$21.2M	$34.9M	$34.9M	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)